A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006120/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
提供机构：
Vivli
创建时间：
2020-10-30
